Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lianyun Zhao is active.

Publication


Featured researches published by Lianyun Zhao.


Bioorganic & Medicinal Chemistry Letters | 2010

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.

Lianyun Zhao; Yingxin Zhang; Chaoyang Dai; Timothy J. Guzi; Derek Wiswell; Wolfgang Seghezzi; David Parry; Thierry O. Fischmann; M. Arshad Siddiqui

A novel series of CHK1 inhibitors based on thienopyridine template has been designed and synthesized. These inhibitors maintain critical hydrogen bonding with the hinge and conserved water in the ATP binding site. Several compounds show single digit nanomolar CHK1 activities. Compound 70 shows excellent enzymatic activity of 1 nM.


Bioorganic & Medicinal Chemistry Letters | 2011

2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.

Chaoyang Dai; Dansu Li; Janeta Popovici-Muller; Lianyun Zhao; Vinay Girijavallabhan; Kristin E. Rosner; Brian J. Lavey; Razia Rizvi; Bandarpalle B. Shankar; Michael K.C. Wong; Zhuyan Guo; Peter Orth; Corey O. Strickland; Jing Sun; Xiaoda Niu; Shiying Chen; Joseph A. Kozlowski; Daniel Lundell; John J. Piwinski; Neng-Yang Shih; M. Arshad Siddiqui

TNF-α converting enzyme (TACE) inhibitors are promising agents to treat inflammatory disorders and cancer. We have investigated novel tartrate diamide TACE inhibitors where the tartrate core binds to zinc in a unique tridentate fashion. Incorporating (R)-2-(2-N-alkylaminothiazol-4-yl)pyrrolidines into the left hand side amide of the tartrate scaffold led to the discovery of potent and selective TACE inhibitors, some of which exhibited good rat oral bioavailability.


Bioorganic & Medicinal Chemistry Letters | 2013

Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.

Zhaoyang Meng; Jeffrey P. Ciavarri; Andrew Mcriner; Yinyan Zhao; Lianyun Zhao; Panduranga Adulla P. Reddy; Xingmin Zhang; Thierry O. Fischmann; Charles Whitehurst; M. Arshad Siddiqui

Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2.


Bioorganic & Medicinal Chemistry Letters | 2014

Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor

Yongqi Deng; Gerald W. Shipps; Lianyun Zhao; M. Arshad Siddiqui; Janeta Popovici-Muller; Patrick J. Curran; Jose S. Duca; Alan Hruza; Thierry O. Fischmann; Vincent Madison; Rumin Zhang; Charles Wayne Mcnemar; Todd Mayhood; Rosalinda Syto; Allen Annis; Paul Kirschmeier; Emma M. Lees; David Parry; William T. Windsor

A new class of quinoline-based kinase inhibitors has been discovered that both disrupt cyclin dependent 2 (CDK2) interaction with its cyclin A subunit and act as ATP competitive inhibitors. The key strategy for discovering this class of protein-protein disrupter compounds was to screen the monomer CDK2 in an affinity-selection/mass spectrometry-based technique and to perform secondary assays that identified compounds that bound only to the inactive CDK2 monomer and not the active CDK2/cyclin A heterodimer. Through a series of chemical modifications the affinity (Kd) of the original hit improved from 1 to 0.005μM.


Archive | 2008

Heterocyclic amide compounds as protein kinase inhibitors

Panduranga Adulla P. Reddy; Lianyun Zhao; Praveen K. Tadikonda; Tzu Tshin Wong; Shuyi Tang; Luis Torres; David F. Cauble; Timothy J. Guzi; M. Arshad Siddiqui


Archive | 2005

Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders

Zhuyan Guo; Peter Orth; Zhaoning Zhu; Robert D. Mazzola; Tin Yau Chan; Henry A. Vaccaro; Kittrick Brian Mc; Joseph A. Kozlowski; Brian J. Lavey; Guowei Zhou; Sunil Paliwal; Shing-Chun Wong; Neng-Yang Shih; Pauline C. Ting; Kristin E. Rosner; Gerald W. Shipps; M. Arshad Siddiqui; David B. Belanger; Chaoyang Dai; Dansu Li; Vinay M. Girijavallabhan; Janeta Popovici-Muller; Wensheng Yu; Lianyun Zhao


Bioorganic & Medicinal Chemistry Letters | 2013

Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.

Xiaohua Huang; Cliff C. Cheng; Thierry O. Fischmann; Jose S. Duca; Matthew Richards; Praveen K. Tadikonda; Panduranga Adulla P. Reddy; Lianyun Zhao; M. Arshad Siddiqui; David Parry; Nicole Davis; Wolfgang Seghezzi; Derek Wiswell; Gerald W. Shipps


Archive | 2007

2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS

Gerald W. Shipps; Cliff C. Cheng; Xiaohua Huang; Thierry O. Fischmann; Jose S. Duca; Matthew Richards; Hongbo Zeng; Binyuan Sun; Panduranga Adulla P. Reddy; Lianyun Zhao; Shuyi Tang; Tzu T. Wong; Praveen K. Tadikonda; Luis Torres; M. Arshad Siddiqui; Michael P. Dwyer; Kartik M. Keertikar; Timothy J. Guzi


Archive | 2010

NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Lianyun Zhao; Duan Liu; Shuyi Tang; Amit K. Mandal; Umar Faruk Mansoor; Lalanthi Dilrukshi Vitharana; Panduranga Adulla P. Reddy; M. Arshad Siddiqui


Archive | 2006

Novel high affinity quinoline-based kinase ligands

Yongqi Deng; Patrick J. Curran; Gerald W. Shipps; Lianyun Zhao; M. Arshad Siddiqui; Janeta Popovici-Muller; Jose S. Duca; Alan Hruza; Thierry O. Fischmann; Vincent Madison; Rumin Zhang; Charles Wayne Mcnemar; Todd Mayhood; William T. Windsor; Emma M. Lees; David Parry

Collaboration


Dive into the Lianyun Zhao's collaboration.

Researchain Logo
Decentralizing Knowledge